0001767398-24-000003.txt : 20240311 0001767398-24-000003.hdr.sgml : 20240311 20240311132503 ACCESSION NUMBER: 0001767398-24-000003 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240311 EFFECTIVENESS DATE: 20240311 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Melt Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001767398 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 611888986 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-489452 FILM NUMBER: 24737365 BUSINESS ADDRESS: STREET 1: 5511 VIRGINIA WAY STREET 2: SUITE 300 CITY: BRENTWOOD STATE: TN ZIP: 37027 BUSINESS PHONE: 8587044042 MAIL ADDRESS: STREET 1: 5511 VIRGINIA WAY STREET 2: SUITE 300 CITY: BRENTWOOD STATE: TN ZIP: 37027 D/A 1 primary_doc.xml X0708 D/A LIVE 0001767398 Melt Pharmaceuticals, Inc. 5511 VIRGINIA WAY SUITE 300 BRENTWOOD TN TENNESSEE 37027 (629) 802-9555 DELAWARE None None Corporation true 2019 Larry Dillaha 5511 Virginia Way Suite 300 Brentwood TN TENNESSEE 37027 Executive Officer Director Brad Osborne 5511 Virginia Way Suite 300 Brentwood TN TENNESSEE 37027 Executive Officer Pharmaceuticals Decline to Disclose 06b true 0001767398-24-000002 2023-07-28 false true false 0 Newbridge Securities Corporation None None None 1200 North Federal Highway Suite 400 Boca Raton FL FLORIDA 33432 AL ALABAMA AZ ARIZONA AR ARKANSAS CA CALIFORNIA CO COLORADO CT CONNECTICUT DE DELAWARE FL FLORIDA GA GEORGIA IL ILLINOIS KY KENTUCKY MD MARYLAND MA MASSACHUSETTS MI MICHIGAN MN MINNESOTA MO MISSOURI NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA OH OHIO OK OKLAHOMA PA PENNSYLVANIA TN TENNESSEE TX TEXAS UT UTAH VA VIRGINIA WA WASHINGTON WI WISCONSIN false 47763600 41552780 6210820 The Total Offering Amount was increased to account for the issuance of securities to settle certain outstanding indebtedness. false 300 1736850 0 In addition to the Sales Commissions noted above, the placement agent may recieve compensation warrants to purchase up to a maximum of 105,882 shares. 0 true false Melt Pharmaceuticals, Inc. /s/ Brad Osborne Brad Osborne Chief Financial Officer 2024-03-11